Gilead Says IDEAL Phase 3 Study Met ALP Endpoint for Livdelzi

Gilead said the Phase 3 IDEAL study met its ALP normalization composite endpoint in a broader PBC population. At week 52, 75.4% of Livdelzi-treated patients achieved the endpoint; the supplied report gives no comparison figure.